About: covid:PMC7360763

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7360763 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Pichlmair, Andreas Baumbach, Jan Blumenthal, David Galindez, Gihanna Kacprowski, Tim List, Markus Matschinske, Julian Nasirigerdeh, Reza Oubounyt, Mhaned Pauling, Josch Rose, Tim Sadegh, Sepideh Salgado-Albarrán, Marisol Späth, Julian Stukalov, Alexey Wenke, Nina Yuan, Kevin
is schema:about of	named entity 'SARS-CoV-2' named entity 'dengue' named entity 'Tocilizumab' named entity 'biological processes' named entity 'Masitinib' named entity 'Steiner tree' named entity 'IC50' named entity 'experimental validation' named entity 'oxygen' named entity 'IFIT1' named entity 'influenza viruses' named entity 'interactome' named entity 'Deferoxamine' named entity 'ACE inhibitors' named entity 'OAS2' named entity 'COVID' named entity 'drug targets' named entity 'degree centrality' named entity 'infectious disease research' named entity 'biological pathway' named entity 'clinical research' named entity 'general idea' named entity 'immunostimulants' named entity 'Redis' named entity 'closeness centrality' named entity 'SARS-CoV-2 virus' named entity 'investigational drug' named entity 'COVID' named entity 'PPI' named entity 'Wuhan' named entity 'TrustRank' named entity 'closeness centrality' named entity 'Ruxolitinib' named entity 'methylene blue' named entity 'angiotensin-converting enzyme (ACE) inhibitor' named entity 'drug targets' named entity 'DrugBank' named entity 'viral proteins' named entity 'network medicine' named entity 'interactomes' named entity 'virus' named entity 'infection' named entity 'probability' named entity 'drug targets' named entity 'Steiner tree problem' named entity 'approved drugs' named entity 'proteins expressed' named entity 'data integration' named entity 'set of proteins' named entity 'drug repurposing' named entity 'SARS-CoV-2 virus' named entity 'Ruxolitinib' named entity 'DDX58' named entity 'Enalaprilat' named entity 'network medicine' named entity 'drug repurposing' named entity 'SARS-CoV-2' named entity 'gene expression' named entity 'degree centrality' named entity 'systems medicine' named entity 'antimalarial drugs' named entity 'inflammatory' named entity 'COVID-19' named entity 'viral proteins' named entity 'SARS-CoV-2 virus' named entity 'closeness centrality' named entity 'drug repurposing' named entity 'immune-mediated' named entity 'viral infection' named entity 'methemoglobinemia' named entity 'damping factor' named entity 'Hydroxychloroquine' named entity 'virus' named entity 'safe and effective' named entity 'viral infection' named entity 'vaccines' named entity 'virus' named entity 'subnetwork' named entity 'user interface' named entity 'EC50' named entity 'binding affinity' named entity 'ACE2' named entity 'virus'

Attributes

Values

Creator

Pichlmair, Andreas
Baumbach, Jan
Blumenthal, David
Galindez, Gihanna
Kacprowski, Tim
List, Markus
Matschinske, Julian
Nasirigerdeh, Reza
Oubounyt, Mhaned
Pauling, Josch
Rose, Tim
Sadegh, Sepideh
Salgado-Albarrán, Marisol
Späth, Julian
Stukalov, Alexey
Wenke, Nina
Yuan, Kevin

is schema:about of

named entity 'SARS-CoV-2'
named entity 'dengue'
named entity 'Tocilizumab'
named entity 'biological processes'
named entity 'Masitinib'
named entity 'Steiner tree'
named entity 'IC50'
named entity 'experimental validation'
named entity 'oxygen'
named entity 'IFIT1'
named entity 'influenza viruses'
named entity 'interactome'
named entity 'Deferoxamine'
named entity 'ACE inhibitors'
named entity 'OAS2'
named entity 'COVID'
named entity 'drug targets'
named entity 'degree centrality'
named entity 'infectious disease research'
named entity 'biological pathway'
named entity 'clinical research'
named entity 'general idea'
named entity 'immunostimulants'
named entity 'Redis'
named entity 'closeness centrality'
named entity 'SARS-CoV-2 virus'
named entity 'investigational drug'
named entity 'COVID'
named entity 'PPI'
named entity 'Wuhan'
named entity 'TrustRank'
named entity 'closeness centrality'
named entity 'Ruxolitinib'
named entity 'methylene blue'
named entity 'angiotensin-converting enzyme (ACE) inhibitor'
named entity 'drug targets'
named entity 'DrugBank'
named entity 'viral proteins'
named entity 'network medicine'
named entity 'interactomes'
named entity 'virus'
named entity 'infection'
named entity 'probability'
named entity 'drug targets'
named entity 'Steiner tree problem'
named entity 'approved drugs'
named entity 'proteins expressed'
named entity 'data integration'
named entity 'set of proteins'
named entity 'drug repurposing'
named entity 'SARS-CoV-2 virus'
named entity 'Ruxolitinib'
named entity 'DDX58'
named entity 'Enalaprilat'
named entity 'network medicine'
named entity 'drug repurposing'
named entity 'SARS-CoV-2'
named entity 'gene expression'
named entity 'degree centrality'
named entity 'systems medicine'
named entity 'antimalarial drugs'
named entity 'inflammatory'
named entity 'COVID-19'
named entity 'viral proteins'
named entity 'SARS-CoV-2 virus'
named entity 'closeness centrality'
named entity 'drug repurposing'
named entity 'immune-mediated'
named entity 'viral infection'
named entity 'methemoglobinemia'
named entity 'damping factor'
named entity 'Hydroxychloroquine'
named entity 'virus'
named entity 'safe and effective'
named entity 'viral infection'
named entity 'vaccines'
named entity 'virus'
named entity 'subnetwork'
named entity 'user interface'
named entity 'EC50'
named entity 'binding affinity'
named entity 'ACE2'
named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software